Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR | Market Cap | 191.49M +2.2% |
| Revenue (ttm) | 55.86M +0.6% |
| Net Income | -57.17M |
| EPS | -0.57 |
| Shares Out | 72.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,898 |
| Open | 2.720 |
| Previous Close | 2.738 |
| Day's Range | 2.620 - 2.746 |
| 52-Week Range | 2.030 - 4.840 |
| Beta | 2.77 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 15, 2026 |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with... [Read more]
Financial Performance
In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to dev...
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline
(RTTNews) - Cellectis (CLLS), a clinical-stage biotechnology company developing gene-edited cell and gene therapies, reported financial results for the second quarter of 2026.
Cellectis reports Q2 adjusted EPS (35c) vs (40c) last year
Reports Q2 revenue $14.5M, consensus $9.49M. “The lasme-cel and eti-cel clinical results presented at EHA 2026 are promising for patients with relapsed or refractory B-cell malignancies. We are also p...
Cellectis Earnings release: H1 2026
Cellectis released its H1 2026 earnings on August 6, 2026, summarizing the period's financial results.
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis to Report Second Quarter Financial Results on August 6, 2026
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic condition...
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Cellectis Slides: FY 2026
Cellectis has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 11, 2026.
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
Cellectis (CLLS) announced that the FDA granted Regenerative Medicine Advanced Therapy, or RMAT, designation to lasmecabtagene timgedleucel, its CD22-targeting allogeneic CAR-T cell therapy product ca...
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Cellectis initiated with an Overweight at Barclays
Barclays initiated coverage of Cellectis (CLLS) with an Overweight rating and $9 price target The company is focused on the development of allogenic CAR-T therapeutics for various cancers, the analyst...
Cellectis Slides: Corporate presentation
Cellectis has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...
Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress
Cellectis (CLLS) announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association annual congress, on June 11-14, 2026, in Stockholm, Sweden. The...
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to devel...
Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year
Reports Q1 revenue $7.5M, consensus $9.37M. “The interim pivotal data published by Allogene on cema-cel, a product originally developed by Cellectis (CLLS) as UCART19, are a proud validation of our…
Cellectis sees cash runway into 4Q27
As of March 31, 2026, Cellectis (CLLS) had $188 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current financial assets. The Company believes its...
Cellectis Reports Financial Results for the First Quarter 2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 ...
Cellectis Earnings release: Q1 2026
Cellectis released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Cellectis Earnings release: Q1 2026
Cellectis released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Cellectis to Report First Quarter Financial Results on May 11, 2026
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...